On Wednesday, OXiGENE Inc (NASDAQ:OXGN)’s shares declined -15.45% to $0.930.
OXiGENE, Inc. (OXGN), a biopharmaceutical company developing novel therapies for treatment of cancer, declared its plans for the further advancement of its lead investigational drug, CA4P (combretastatin A4 phosphate, or fosbretabulin). This follows a thorough evaluation of the company’s pipeline opportunities.
OXiGENE’s advancement plans comprise two phase 2/3 clinical trials evaluating whether CA4P improves the current standard-of-care in patients who have failed to respond to initial treatment. Both trials planned by the company are designed as two stage, phase 2/3 studies. The first stage of each trial would be a randomized, investigator-blinded, placebo-controlled study with up to 80 patients. The second stage of each trial would be a large, double-blind, placebo-controlled, confirmatory phase 3 study, the start of which would be triggered by a demonstration of efficacy in the first stage. Each trial is designed so that a particularly robust efficacy signal in the first stage would accelerate the timing of the transition into the larger second stage phase 3 portion.
OXiGENE, Inc., a biopharmaceutical company, focuses on the development of vascular disrupting agents to treat cancer in the United States. Its principal clinical stage product comprises fosbretabulin tromethamine, a reversible tubulin binding agent, which has accomplished Phase II clinical trial for treating recurrent ovarian cancer; and in Phase II clinical trial for treating gastrointestinal neuroendocrine tumors.
Duke Realty Corp (NYSE:DRE)’s shares dropped -0.37% to $19.05.
Duke Realty Corporation (DRE), will hold its quarterly conference call to talk about third quarter results on Thursday, October 29th, 2015, at 3:00 p.m. Eastern Time. Duke Realty will release its Third Quarter 2015 earnings on Wednesday, October 28th, after market close.
The public may access the conference through a live audio webcast accessible on the investor relations section of Duke Realty’s website at www.dukerealty.com. Supplemental materials will be posted to the investor relations section of the Company’s website preceding to the conference call. Institutional investors can also access the conference via Thomson Reuters’ password-protected event administration site, StreetEvents (www.streetevents.com). Shortly after the conclusion of the conference call, investors can access a replay of the webcast on the Company’s website.
Duke Realty Corporation is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It offers a single point of responsibility for all aspects of a project, counting leasing, asset administration, construction and development.
At the end of Wednesday’s trade, AstraZeneca plc (ADR)(NYSE:AZN)‘s shares surged 1.73% to $31.82.
AstraZeneca (AZN) declared that BRILINTA® (ticagrelor) 60-mg tablets are now accessible in US pharmacies. On September 3, 2015, the US Food and Drug Administration (FDA) approved a new 60-mg dosage strength for BRILINTA to be used in patients with a history of heart attack beyond the first year. BRILINTA is approved to reduce the rate of cardiovascular (CV) death, myocardial infarction ([MI], also known as heart attack) and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, BRILINTA is superior to clopidogrel. BRILINTA is the first and only FDA approved oral antiplatelet to demonstrate superior reductions in CV death vs clopidogrel at 12 months.
The dosing of BRILINTA in the administration of ACS is 90 mg twice daily during the first year after an ACS event. After one year, patients with a history of heart attack can now be treated with 60 mg twice daily. BRILINTA must be used with a daily maintenance dose of aspirin of 75-100mg.
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide.
IMAX Corporation (USA)(NYSE:IMAX), ended its Wednesday’s trading session with 5.46% gain, and closed at $33.79.
IMAX Corporation (IMAX) declared that IMAX China Holding, Inc., a Cayman Islands company, has determined the offer price for the offering (the “Offering”) of its shares to be listed on the Hong Kong Stock Exchange Limited.
IMAX China recently determined the offer price of HK$31.0 (US$4.0) per share for the Offering of 62,000,000 shares (before the over-allotment option) that was declared on September 22, 2015. IMAX China is predictable to issue 17,825,000 new shares and a number of selling shareholders, counting a wholly owned partner of IMAX Corporation, are predictable to sell a total of 44,175,000 sale shares. The 62,000,000 shares represent about 17.4% of the enlarged issued share capital of IMAX China. IMAX China is predictable to receive net proceeds of about HK$450.8 million (US$58.2 million), after deducting commissions in connection with the Offering. IMAX Corporation, through a wholly owned partner, is predictable to receive HK$664.2 million (US$85.7 million) from the sale of 22,087,400 sale shares and up to HK$804.0 million (US$103.7 million) if the over-allotment option is exercised in full, after deducting commissions in connection with the Offering.
IMAX China plans to use the majority of the net proceeds to expand the IMAX network of theatres in China, in addition to to build up its inventory of IMAX theatre systems. The offering is predictable to close on or about October 8, 2015 (Hong Kong time), subject to satisfaction of customary closing conditions. The shares are predictable to be listed on the Hong Kong Stock Exchange on the same day.
IMAX Corporation, together with its auxiliaries, operates as an entertainment technology company specializing in motion picture technologies and presentations worldwide. The company operates in seven segments: IMAX Systems, Theater System Maintenance, Joint Revenue Sharing Arrangements, Film Production and IMAX Digital Re-Mastering (DMR), Film Distribution, Film Post-Production, and Other. The IMAX Systems segment designs, manufactures, sells, or leases IMAX theater projection system equipment.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
